Source:http://linkedlifedata.com/resource/pubmed/id/20855565
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2010-11-10
|
| pubmed:abstractText |
A low level of HDL-C is the most common plasma lipid abnormality observed in men with established coronary heart disease (CHD). To identify allelic variants associated with susceptibility to low HDL-C and CHD, we examined 60 candidate genes with key roles in HDL metabolism, insulin resistance, and inflammation using samples from the Veterans Affairs HDL Intervention Trial (VA-HIT; cases, n = 699) and the Framingham Offspring Study (FOS; controls, n = 705). VA-HIT was designed to examine the benefits of HDL-raising with gemfibrozil in men with low HDL-C (?40 mg/dl) and established CHD. After adjustment for multiple testing within each gene, single-nucleotide polymorphisms (SNP) significantly associated with case status were identified in the genes encoding LIPC (rs4775065, P < 0.0001); CETP (rs5882, P = 0.0002); RXRA (rs11185660, P = 0.0021); ABCA1 (rs2249891, P = 0.0126); ABCC6 (rs150468, P = 0.0206; rs212077, P = 0.0443); CUBN (rs7893395, P = 0.0246); APOA2 (rs3813627, P = 0.0324); SELP (rs732314, P = 0.0376); and APOC4 (rs10413089, P = 0.0425). Included among the novel findings of this study are the identification of susceptibility alleles for low HDL-C/CHD risk in the genes encoding CUBN and RXRA, and the observation that genetic variation in SELP may influence CHD risk through its effects on HDL.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0022-2275
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3524-32
|
| pubmed:meshHeading |
pubmed-meshheading:20855565-Aged,
pubmed-meshheading:20855565-Alleles,
pubmed-meshheading:20855565-Case-Control Studies,
pubmed-meshheading:20855565-Cholesterol, HDL,
pubmed-meshheading:20855565-Continental Population Groups,
pubmed-meshheading:20855565-Coronary Disease,
pubmed-meshheading:20855565-European Continental Ancestry Group,
pubmed-meshheading:20855565-Gemfibrozil,
pubmed-meshheading:20855565-Genetic Predisposition to Disease,
pubmed-meshheading:20855565-Genetic Variation,
pubmed-meshheading:20855565-Humans,
pubmed-meshheading:20855565-Hypolipidemic Agents,
pubmed-meshheading:20855565-Inflammation,
pubmed-meshheading:20855565-Insulin Resistance,
pubmed-meshheading:20855565-Male,
pubmed-meshheading:20855565-Metabolic Networks and Pathways,
pubmed-meshheading:20855565-Middle Aged,
pubmed-meshheading:20855565-Polymorphism, Single Nucleotide,
pubmed-meshheading:20855565-United States,
pubmed-meshheading:20855565-United States Department of Veterans Affairs
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.
|
| pubmed:affiliation |
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|